Genaera Corporation, a biopharmaceutical company, engages in the research and development of medicines with focus on antiangiogenesis and respiratory diseases. The company’s primary product EVIZON is under Phase II and Phase III clinical trials to treat ophthalmic indications, specifically the ‘wet’ form of age related macular degeneration. It is also developing Squalamine Lactate, a Phase II clinical trial product, for the treatment of cancerous solid tumors; LOMUCIN, a Phase II clinical trial product, to treat the overproduction of mucus secretions involved in chronic respiratory disease; and interleukin-9 antibody, a respiratory treatment based on the discovery of a...